The B-cell inhibitors market is experiencing robust growth, driven by the rising prevalence of the addressable patient population, which incl ...

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in ...

At current levels, we believe AMGN scores above BMY, buoyed by solid fundamentals and recent positive estimate revisions.

Inebilizumab was especially effective for patients with pancreatic and biliary immunoglobulin G4-related disease, with ...

High rates of biologic naivety, limited switching, and ongoing unmet needs across the gMG landscape create opportunity for brand differentiation.EXTON, PA, May 15, 2025 (GLOBE NEWSWIRE) -- The ...

Credit: Getty Images. Are you staying current with the latest FDA approvals? Test your knowledge with our monthly quiz. How well do you know the latest drug approvals? Put your clinical knowledge ...

Inebilizumab (Uplizna) treatment significantly reduced the risk of flares in patients who had IgG4-related disease (IgG4-RD) with involvement in the pancreas, bile ducts, or liver, according to a ...

Growth is also expected from drugs acquired from Horizon, including Tepezza for thyroid eye disease, Krystexxa for gout, and Uplizna for neuromyelitis optica spectrum disorder. Amgen is currently ...

At the start of this month, the firm received an expanded FDA label approval for Uplizna. The FDA has approved it as the first treatment for Immunoglobulin G4-related disease (IgG4-RD) for adults.

The acquisition of Horizon brought three new potentially blockbuster drugs into Amgen’s portfolio – Tepezza (for the treatment of thyroid eye disease), Krystexxa (gout), and Uplizna ...